PHRI’s OCEANIC-STROKE study has successfully completed recruitment enrolling approximately 12,300 patients across 38 countries, surpassing its initial target of 9,300 participants.
OCEANIC-STROKE is a multicenter, international, randomized, placebo-controlled, phase III study. It investigates asundexian, a new anticoagulant under development that inhibits Factor XI. This treatment aims to reduce the risk of bleeding while providing additional treatment options for patients who have recently suffered a non-cardioembolic ischemic stroke or temporary stroke-like symptoms.
Co-led by scientist Mike Sharma, Senior scientist Ashkan Shoamanesh and Scientist Raed Joundi, the study aims to evaluate whether asundexian, when added to standard antiplatelet therapy, reduces the risk of a recurrent stroke in these participants.
The Hamilton-based team includes Amanda Taylor (Associate Program Manager), Jodi Miller (Research Project Manager III), Samantha Block (Research Project Coordinator III), Sadia Aman (Research Project Coordinator II), Yongning Ou (Research Data Specialist II), Catrina Linton (Research Project Coordinator II), Justin Hipolito (Research Project Coordinator I), Kumiko Stefani (Research Administrative Assistant).
The study recruited participants from 38 countries, including Argentina, Australia, Brazil, Canada, China, France, Germany, India, Japan, the United Kingdom, and the United States, among others.
Congratulations to the study team in Canada and around the globe on this remarkable achievement!
